“Our team remains deeply committed to executing our plans in 2024, and I’m proud of the strides we’ve made in the third quarter. We expect enrollment completion of our Phase 2 ALTITUDE-AD study in the first half of 2025,” said Daniel O’Connell, Chief Executive Officer of Acumen (ABOS). “Additionally, we anticipate topline results from our Phase 1 healthy volunteer study investigating subcutaneous sabirnetug in the first quarter of 2025. With our clinical program gaining momentum and sabirnetug’s unique selectivity for toxic amyloid beta oligomers, we are excited about the potential to offer a next-generation treatment for early Alzheimer’s disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- ABOS Earnings this Week: How Will it Perform?
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Acumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trial
- Acumen to deliver late-breaking presentation on ACU193 at CTAD conference
- Acumen extends collaboration with Lonza